Case In Point

16,000-Patient, Global Respiratory Trial that was Findings Free

About Client

Everest was selected to provide critical data management and statistical services for a major pharmaceutical company’s global Phase III respiratory study. The study spanned 26 countries, 950 sites, and involved more than 16,000 patients screened and 8,500 randomized ​over 6 years.

Challenge

The trial’s scale and complexity posed significant operational and statistical challenges, including:

  • Managing large volumes of global clinical data
  • Ensuring consistency and quality across diverse geographies and clinical teams
  • Delivering high-stakes data outputs for submission under tight timelines
  • Maintaining quality and compliance throughout a lengthy multi-year trial

Solution

  • Delivered Data Management, Biostatistics, Statistical Programming, IWRS, DSMB support, and CDISC data preparation
  • Designed and launched the study database; provided exceptional CRA and site user training
  • Executed a proactive data cleaning strategy with smooth soft-locks by site, country, and region
  • Successfully managed DSMB activities to the highest quality standards
  • Developed and adhered to rigorous SOPs and work instructions across teams

Results

  • Final database lock completed within 2 weeks of Last Patient Last Visit
  • Interim Analysis delivered successfully
  • Top-line results finalized within 5 business days
  • Multiple dry-runs enabled more than 1,000 analysis tables, listings, and figures delivered within 2 months of database lock
futuristic medical banner with copy space, featuring lungs healthcare, asthma treatment, and respiratory cancer diagnosis in a clinical hospital environment focused on patient care

The FDA and EMA Inspection Reports had 0 inspection findings on the work performed by Everest.